Human iPSC-derived cerebral organoids reveal oxytocin-mediated protection against amyloid-β pathology.
Level 5 - mechanism / opinion, no new human data
In vitro bench research using human iPSC-derived cerebral organoids (mechanism-based/preclinical model).
PubMed 40654516 · doi:10.1016/j.reth.2025.06.013
What was done
Human cerebral organoids (hCOs) generated from induced pluripotent stem cells (iPSCs) were used to model early Alzheimer's disease pathology. Organoids were exposed to 3 µM amyloid-β (Aβ 1–42) for 48 hours to induce toxicity. The protective effects of oxytocin (OXT) pretreatment were assessed using immunohistochemistry, RT-qPCR, calcium imaging, and multielectrode array (MEA) electrophysiology. Microglial involvement was evaluated via Iba1/OXTR immunostaining and TREM2 expression analysis.
What was found
The abstract reports directional findings without numerical values, effect sizes, or test statistics: - Aβ exposure induced Aβ outer-layer deposition, suppressed neural network activity, and increased apoptotic markers. - OXT pretreatment reduced Aβ deposition and caspase-3-mediated apoptosis in a concentration-dependent manner. - OXT restored calcium oscillations and MEA-recorded neuronal network activity. - OXT enhanced microglial recruitment to Aβ deposits and upregulated TREM2 expression; OXTR was confirmed to co-localize on Iba1-positive microglia.
Why it matters
This study provides mechanistic in vitro evidence that oxytocin can directly modulate human microglia to enhance TREM2-associated Aβ clearance and rescue neuronal firing deficits in a 3D cellular model of Alzheimer's pathology.
Limits
Findings derive entirely from an in vitro organoid model lacking a functional vasculature, systemic immunity, and blood-brain barrier dynamics. The abstract provides no exact quantitative metrics, sample sizes (number of organoids, iPSC lines, or experimental replicates), or specific tested concentrations of oxytocin. Because oxytocin was applied as a pretreatment, therapeutic efficacy against established Aβ pathology remains unmeasured.
Cited by
- supports In animal models of Alzheimer's disease, oxytocin has been shown to reduce the toxicity of amyloid-beta plaques.